Cardio-oncology & otherSecondary analysis
Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy
- Secondary analysis of the STOP-CA randomised trial
- double-blind
- multicentre
- 9 academic centres in the US and Canada
- post hoc end points
Authors' conclusion
Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy.
Study context
- Population
- Patients with newly diagnosed lymphoma scheduled for anthracycline-based chemotherapy, no clinical indication for a statin152 with paired pulse wave velocity (PWV) data
- Participants
- 300 patients
- Comparison
- Atorvastatin vs placebo
- Atorvastatinn = 150
- Placebon = 150reference
- Primary endpoint
- ≥1 SD increase in CMR-derived aortic arch pulse wave velocity (PWV) and ≥1 SD decrease in ascending aortic distensibility (AAD)
- Follow-up
- 12 months
Primary result
≥1 SD increase (0.8 m per second) in PWV
Odds ratio
0.05
95% CI 0.02–0.16
P < 0.001
Events by treatment group
Atorvastatin vs Placebo
OR 0.05 (95% CI 0.02–0.16); P < 0.001
As reported in the abstract
Secondary outcomes
≥1 SD decrease (1.8 × 10-3 mm Hg-1) in AAD · 12 months
| Outcome | mean LVEF decline (95% CI) | P value |
|---|---|---|
| LVEF decline associated with ≥1 SD increase in PWV | 2.70% (−4.65% to −0.81%) | P = 0.006 |
- ≥1 SD decrease (1.8 × 10-3 mm Hg-1) in ascending aortic distensibility (AAD): 168 with paired aortic distensibility (AD) data
PWV values, baseline vs 12 months
- Atorvastatin: remained similar, mean (SD) 6.5 (1.9) vs 6.5 (2.0) m per second
- Placebo: increased, 5.7 (1.8) vs 6.8 (2.0) m per second
Original publication
Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy. JAMA Cardiol. Published 1 January 2026. doi:10.1001/jamacardio.2025.4548
Summarised from the published abstract; every number is checked against it